KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Net Cash Flow (2016 - 2025)

Acadia Pharmaceuticals has reported Net Cash Flow over the past 16 years, most recently at -$81.9 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$81.9 million for Q4 2025, down 149.81% from a year ago — trailing twelve months through Dec 2025 was -$142.8 million (down 206.58% YoY), and the annual figure for FY2025 was -$142.8 million, down 206.58%.
  • Net Cash Flow for Q4 2025 was -$81.9 million at Acadia Pharmaceuticals, down from $4.4 million in the prior quarter.
  • Over the last five years, Net Cash Flow for ACAD hit a ceiling of $176.1 million in Q1 2023 and a floor of -$180.6 million in Q2 2023.
  • Median Net Cash Flow over the past 5 years was -$15.5 million (2023), compared with a mean of -$7.3 million.
  • Biggest five-year swings in Net Cash Flow: soared 366.79% in 2022 and later plummeted 733.51% in 2025.
  • Acadia Pharmaceuticals' Net Cash Flow stood at $52.8 million in 2021, then crashed by 175.74% to -$40.0 million in 2022, then soared by 326.26% to $90.5 million in 2023, then skyrocketed by 81.82% to $164.5 million in 2024, then crashed by 149.81% to -$81.9 million in 2025.
  • The last three reported values for Net Cash Flow were -$81.9 million (Q4 2025), $4.4 million (Q3 2025), and $36.6 million (Q2 2025) per Business Quant data.